HeyJaredJournal of the American Society of Nephrology (JASN)
JASN, the flagship journal of the ASN, publishes basic and clinical science original research articles relevant to the broad discipline of nephrology. The JASN Podcast features discussions with authors of recently published articles.
- Indexed episodes, last 90 days
- 5
- Latest publication
- Sep 25, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 29, 2026
Latest episodes
SHFM3 Is an IS-Dependent IDO1 E3 Ligase (opens the original)
Read excerpt
Drs. Chitalia, Almiron, and Sethuraman discuss their study, "Indoxyl Sulfate Promotes Uremic Arterial and Venous Thrombosis by Stabilizing IDO1 via the E3 Ligase SHFM3," with JASN Deputy Editor Alan S.L. Yu and Junior Associate Editor Kyle Jansson.
Barriers to Kidney Transplantation in the United States (opens the original)
Read excerpt
Drs. Conor Donnelly, Michal A. Mankowski, and Allan B. Massie discuss the findings of their study, "Evaluating Barriers to Kidney Transplantation in the United States," with JASN Deputy Editor David H. Ellison and Junior Associate Editor Nathan H. Raines.
ASN Kidney Translation Series: ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic Syndrome (opens the original)
Read excerpt
This episode of ASN Kidney Translation Podcast explores the ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic (CKM) Syndrome, discussing key recommendations, risk assessment, and strategies to improve kidney, heart, and metabolic outcomes.
APOL1 at the Plasma Membrane and Cytotoxicity (opens the original)
Read excerpt
Dr. Oyindamola Christiana Adebayo discusses the results of her study, "Expression of Apolipoprotein L1 Risk Variants at the Plasma Membrane and Haplotype-Dependent Cytotoxicity," on behalf of her coauthors, with JASN Deputy Editor David H. Ellison.
ASN Kidney Translation Series: Cardiovascular-Kidney-Metabolic (CKM) Syndrome Advances (opens the original)
Read excerpt
ASN Kidney Translation explores advances in Cardiovascular-Kidney-Metabolic syndrome, including building a cardio-nephrology service (Kidney360), cardiorenal benefits of SGLT2 inhibitors & GLP-1 receptor agonists (JASN), & PREVENT risk prediction (CJASN).
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Not enough subject data for this period yet.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.
See coverage about Journal of the American Society of Nephrology (JASN)